Peptide Lab

CJC-1295 (With DAC)

$49.99

In stock

CJC-1295 is an investigational synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a hormone that signals the pituitary gland to release growth hormone. Research has examined its ability to increase growth hormone and insulin-like growth factor 1 (IGF-1), a hormone involved in growth and tissue metabolism.

SKURC-ST-CJC1295D-5MG
ManufacturerStrandix Peptides
FormLyophilized Vial
Strength5mg
Size3 mL Vial
Reported ResultSee matching batch report
StockIn stock
Documentation StatusClient-supplied report available

Product Description

CJC-1295 is an investigational synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a hormone that signals the pituitary gland to release growth hormone. Research has examined its ability to increase growth hormone and insulin-like growth factor 1 (IGF-1), a hormone involved in growth and tissue metabolism.

What research has shown for CJC-1295 with DAC:

Increased growth hormone: Two randomized, placebo-controlled trials in healthy adults found dose-dependent increases in average growth hormone levels lasting at least six days after a single administration.

Increased IGF-1: The same trials reported elevated IGF-1 levels lasting approximately 9–11 days after a single administration.

Extended circulation time: Researchers estimated a half-life of approximately 5.8–8.1 days, demonstrating the prolonged activity of the DAC formulation.

Preserved growth hormone pulses: A separate human study found that growth hormone continued to be released in pulses while baseline and average levels increased. Pulse frequency and magnitude were not significantly changed.

Storage and handling: Keep sealed, dry, and protected from heat and direct light unless the final product label or COA states otherwise. Maintain the product with its matching batch record.

For laboratory research use only. Not for human or animal consumption, personal use, dietary supplementation, wellness, performance, diagnosis, treatment, cure, or prevention.
Lab analysis

Third-party testing status.

Batch / LotReported ResultTestedPartnerStatusDocument
CD5/2025-12-18-B99.061%; 99.056%Jan 5, 2026JanoshikClient-supplied reportView COA